PACLITAXELCARBOPLATINPROGRESSION-free survivalObjective: Incompletely resected epithelial ovarian cancer represents a poor prognostic subset of patients. Novel treatment strategies are needed to improve outcomes for this population. We evaluated a treatment strategy combining platinum-based chemoth...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1923, 127 (2022). https://doi.org/10.1007/s40278-022-22990-2 Download citation Published10 September 2022 Issue DateSeptember 2022 DOIhttps://doi.org/10.1007/s40278-022-22990-2 Access this article Log in via an institution Buy article PDF...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1955, 121 (2023). https://doi.org/10.1007/s40278-023-38368-3 Download citation Published06 May 2023 Issue DateMay 2023 DOIhttps://doi.org/10.1007/s40278-023-38368-3 Access this article Log in via an institution Subscribe and save Springer...
The requested medication will be used in combination with pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology;or The requested medication will be used in combination with carboplatin and either paclitaxel or albumin-bound paclitaxel for squamous cell histology;or As neoadjuvant t...
In the first neoadjuvant phase (cycles 1-4), patients received intravenous pembrolizumab (200 mg every 3 weeks) or placebo in combination with carboplatin (area under the concentration time curve, 5 mg/mL/min every 3 weeks or 1.5 mg/mL/min weekly) plus paclitaxel (80 mg/m2 w...
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a single agent, is indicated ...
Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or rec...
Treating physicians concerned about poor response may modify the treatment regimen (eg, add carboplatin to the paclitaxel portion of treatment); these cases are counted as non-pCR regardless of response, due to nonadherence to study assignment. Three patients in the pembrolizumab arm and 11 patients...
Background: The treatment-free interval is a significant predictor of worse prognosis and poor response rates of the second-line treatment in patients with carboplatin and paclitaxel (PT)-pretreated, advanced, or recurrent endometrial cancer (EC). Whether lenvatinib plus pembrolizumab still confers a ...
Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 8 (Suppl. 3): A118 abstr. 201, 2020. Available from: URL: http://doi.org/10.1136/jitc-2020-SITC2020.0201 [abstract]...